Three years after Novartis opened a $1 billion research & development facility in Shanghai, the company is shifting the focus of the site from drug discovery to commercial development.
San Francisco-based Atomwise, a company focused on using artificial intelligence for drug discovery, signed three new deals.
In a deal-making morning for South San Francisco-based Genentech, the Roche subsidiary struck three separate transactions with small companies to boost drug development.
Linguamatics, an IQVIA company, will present the webinar “Applications of Natural Language Processing to Transform Real World Data.”
German drugmaker Bayer signed an alliance with Arvinas Inc. to gain access to the U.S. biotech firm’s experimental protein drugs and crop protection technology in a deal worth up to $750 million.
Germany-based Evotec SE followed up a string of collaborations with pharma companies with the $90 million acquisition of Bill & Melinda Gates Foundation-backed Just Biotherapeutics Inc.
Gilead Sciences Inc. and Goldfinch Bio Inc. announced a strategic collaboration to discover, develop and commercialize a pipeline of innovative therapeutics for diabetic kidney disease (DKD) and certain orphan kidney diseases.
Alnylam and Sanofi announced a strategic restructuring of their RNAi therapeutics alliance to streamline and optimize development and commercialization of certain products for rare genetic diseases.
